The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting ...

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be ...

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

The Merck KGaA collaborated with actress and patient advocate Selma Blair for the I’m Ready campaign. When EMD Serono embarked on a campaign to empower patients living with relapsing multiple ...

Merck KGaA starts awareness push to help docs unravel form of MS, opening new front in Sanofi fight Blair first began speaking about her positive experience with Mavenclad last summer. In a video ...

Merck KGaA sees forex-adjusted earnings growth ... Future of Healthcategory· September 2, 2024 Sanofi's mixed fortunes in MS drug trials has market focus on win Sanofi's most advanced multiple ...